Propanc Biopharma Inc. Common Stock (PPCB)
Stock · NASDAQ · Health Care
$1.4as of 8/28/2026
Price chart
Open in TradingViewActive signals
High Beta93.6%
Resistance level
$1.66
Industry
Biotechnology: Pharmaceutical Preparations
About PPCB
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Website
- www.propanc.com/
Fundamentals
- Market cap
- $4.76M
- P/E (trailing)
- —
- P/E (forward)
- —
- EPS (trailing)
- $-25.66
- Dividend yield
- —
- Beta
- 3.35
- Avg. volume
- —
52-week range
$0.95$85.5
Propanc Biopharma Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- PPCBPropanc Biopharma Inc. Common Stock$1.4▼ 37.22%Market cap $4.76MP/E —$0.95$85.5
- RNAZTransCode Therapeutics Inc. Common Stock$2.18▼ 4.39%Market cap $4.52MP/E —$2.24$20.99
- DRMADermata Therapeutics Inc. Common Stock$1.49▲ 1.71%Market cap $4.46MP/E —$0.9509$6.23
- ERNAErnexa Therapeutics Inc. Common Stock$4.57▼ 4.99%Market cap $5.09MP/E —$3.18$71.5
- JUNSJupiter Neurosciences Inc. Common Stock$4.59▼ 6.13%Market cap $4.24MP/E —$4.56$138
- LABTLakewood-Amedex Biotherapeutics Inc. Common Stock$2.3▼ 4.56%Market cap $5.28MP/E —$0.366$9.82
- GOVXGeoVax Labs Inc. Common Stock$0.7195▲ 0.35%Market cap $5.31MP/E —$0.59$19.2
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PPCB Propanc Biopharma Inc. Common Stock | $4.76M | — | $1.4 | ▼ 37.22% | $0.95$85.5 |
| RNAZ TransCode Therapeutics Inc. Common Stock | $4.52M | — | $2.18 | ▼ 4.39% | $2.24$20.99 |
| DRMA Dermata Therapeutics Inc. Common Stock | $4.46M | — | $1.49 | ▲ 1.71% | $0.9509$6.23 |
| ERNA Ernexa Therapeutics Inc. Common Stock | $5.09M | — | $4.57 | ▼ 4.99% | $3.18$71.5 |
| JUNS Jupiter Neurosciences Inc. Common Stock | $4.24M | — | $4.59 | ▼ 6.13% | $4.56$138 |
| LABT Lakewood-Amedex Biotherapeutics Inc. Common Stock | $5.28M | — | $2.3 | ▼ 4.56% | $0.366$9.82 |
| GOVX GeoVax Labs Inc. Common Stock | $5.31M | — | $0.7195 | ▲ 0.35% | $0.59$19.2 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Revolution Medicines’ Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma’s Breakthrough Survival Resultsbenzinga · 8/27/2026
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga · 8/11/2026
- Propanc Biopharma Announces New Preclinical And Translational Data For Lead Candidate PRP In Pancreatic Ductal AdenocarcinomaBenzinga · 8/6/2026
- 12 Health Care Stocks Moving In Wednesday's Intraday SessionBenzinga · 8/5/2026
See the full, filterable feed with live charts on the MarketWall dashboard.